3-iodo-2-methyl-1H-indole | 2033-44-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3-iodo-2-methyl-1H-indole
• CAS: 2033-44-5
• 化学式: C₉H₈IN
• 分子量: 257.074
• InChiKey: FQNMASKRUDYNCK-UHFFFAOYSA-N

物化性质

• 熔点：
  82 °C
• 沸点：
  346.7±22.0 °C(Predicted)
• 密度：
  1.833±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  15.8
• 氢给体数：
  1
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  3-iodo-2-methyl-1H-indole 在 bis-triphenylphosphine-palladium(II) chloride 、 N-溴代丁二酰亚胺(NBS) 、 copper(l) iodide 、 sodium azide 、 偶氮二异丁腈 、 碘 、 四丁基硫酸氢铵 、 三乙胺 、 sodium hydroxide 作用下， 以 四氯化碳 、 硝基甲烷 、 水 、 Petroleum ether 、 苯 为溶剂， 反应 44.0h， 生成 4-iodine-3-phenyl-1-(phenylsulfonyl)-β-carbonline
  参考文献：
  名称：

  Synthesis and cytotoxic activity of 3-phenyl-4-substituted-β-carbolines

  摘要：

  A new class of 3-phenyl-4-substituted-beta carbolines via iodine-mediated electrophilic cyclization as key step were synthesized and their inhibitory activity against three tumor cell lines was evaluated in vitro. It was found that some of the tested compounds showed better cytotoxicity against HeLa and MCF-7 cells than harmine. (C) 2012 Guang Yu Xu. Published by Elsevier B.V. on behalf of Chinese Chemical Society. All rights reserved.

  DOI：

  10.1016/j.cclet.2012.09.010
• 作为产物：
  描述：

  2-甲基吲哚 在 potassium iodide 作用下， 以 乙腈 为溶剂， 反应 6.0h， 以78%的产率得到3-iodo-2-methyl-1H-indole
  参考文献：
  名称：

  电化学催化剂和无氧化剂条件下吲哚衍生物的通用C–H卤化策略

  摘要：

  据报道，一种经济且可扩展的电化学方案可用于吲哚衍生物的区域选择性3C–H卤化。该策略可在温和条件下使用廉价的（伪）卤化物盐作为唯一试剂，获得大量3-碘，3-溴，3-氯和3-硫氰基吲哚衍生物。无需补充电解质盐。

  DOI：

  10.1002/ejoc.201800267

文献信息

• [EN] PYRAZOLOPYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE PYRAZOLOPYRIDINE POUR LE TRAITEMENT DU CANCER
  申请人：GENENTECH INC

  公开号：WO2017205538A1

  公开（公告）日：2017-11-30

  The present invention relates to a compound formula (I): and to salts thereof, wherein R1, R2X, and Y have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders such as cancer, inflammatory disorders and autoimmune diseases.

  本发明涉及一种化合物公式（I）及其盐，其中R1、R2X和Y具有本文中定义的任何值，以及其组合物和用途。这些化合物可用作CBP和/或EP300的抑制剂。还包括包含公式（I）化合物或其药学上可接受的盐的药物组合物，以及在治疗各种CBP和/或EP300介导的疾病，如癌症、炎症性疾病和自身免疫疾病中使用这些化合物和盐的方法。
• INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS
  申请人：Kaila Neelu

  公开号：US20110105509A1

  公开（公告）日：2011-05-05

  Disclosed are compounds of Formula (I): which are useful as antagonists of the CRTH2 receptors. Pharmaceutical compositions containing compounds of Formula (I) and the use of compounds of Formula (I) to treat diseases or disorders that are responsive to inhibition of the binding of endogenous ligands to the CRTH2 receptor are also disclosed. Methods for preparing and using these compounds are further described.

  公开的是以下化合物的结构（I）：这些化合物可用作CRTH2受体的拮抗剂。还公开了含有化合物（I）的药物组合物以及利用化合物（I）治疗对抑制内源配体与CRTH2受体结合响应的疾病或疾病的用途。进一步描述了制备和使用这些化合物的方法。
• [EN] INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7)<br/>[FR] INHIBITEURS DE LA KINASE CYCLINE-DÉPENDANTE 7 (CDK7)
  申请人：SYROS PHARMACEUTICALS INC

  公开号：WO2016058544A1

  公开（公告）日：2016-04-21

  The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase (e.g., CDK7), and therefore induce cellular apoptosis and/or inhibit transcription in the subject.

  本发明提供了式（I）的新化合物及其药学上可接受的盐、溶剂化合物、水合物、互变异构体、立体异构体、同位素标记衍生物及其组合物。还提供了涉及这些化合物或组合物用于治疗或预防增生性疾病（例如，癌症（例如，白血病、黑色素瘤、多发性骨髓瘤）、良性肿瘤、血管生成、炎症性疾病、自身炎症性疾病和自身免疫性疾病）的方法和试剂盒。使用本发明的化合物或组合物治疗患有增生性疾病的受试者可能抑制细胞周期依赖性激酶（例如，CDK7）的异常活性，从而诱导受试者的细胞凋亡和/或抑制转录。
• [EN] POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7)<br/>[FR] INHIBITEURS POLYCYCLIQUES DE KINASE CYCLINE-DÉPENDANTE 7 (CDK7)
  申请人：DANA FARBER CANCER INST INC

  公开号：WO2015058140A1

  公开（公告）日：2015-04-23

  The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, lymphoma, melanoma, multiple myeloma, breast cancer, Ewing' s sarcoma, osteosarcoma, brain cancer, neuroblastoma, lung cancer), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., cyclin-dependent kinase 7 (CDK7), cyclin-dependent kinase 12 (CDK12), or cyclin-dependent kinase 13 (CDK13)), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

  本发明提供了一种新型化合物的公式（I），以及其药用可接受的盐、溶剂合物、水合物、多晶形态、共晶体、互变异构体、立体异构体、同位素标记衍生物、前药和其组合物。还提供了涉及创新化合物或组合物的方法和试剂盒，用于治疗或预防增殖性疾病（例如，癌症（例如，白血病、淋巴瘤、黑色素瘤、多发性骨髓瘤、乳腺癌、尤因氏肉瘤、骨肉瘤、脑癌、神经母细胞瘤、肺癌）、良性肿瘤、血管生成、炎症性疾病、自身炎症性疾病和自身免疫疾病）的方法和试剂盒。使用本发明的化合物或组合物治疗患有增殖性疾病的对象可能抑制激酶的异常活性，如细胞周期依赖性激酶（CDK）（例如，细胞周期依赖性激酶7（CDK7）、细胞周期依赖性激酶12（CDK12）或细胞周期依赖性激酶13（CDK13）），从而在对象中诱导细胞凋亡和/或抑制转录。
• A Versatile C-H Halogenation Strategy for Indole Derivatives under Electrochemical Catalyst- and Oxidant-Free Conditions
  作者：Linhao Sun、Xing Zhang、Zilong Li、Jimei Ma、Zhen Zeng、Hong Jiang

  DOI：10.1002/ejoc.201800267

  日期：2018.9.23

  An economical and scalable electrochemical protocol for regioselective 3C–H halogenation of indole derivatives is reported. This strategy provides access to a host of 3‐iodo‐, 3‐bromo‐, 3‐chloro‐, and 3‐thiocyanoindole derivatives under mild conditions using inexpensive (pseudo)halide salts as the sole reagent. No supplementary electrolyte salt is necessary.

  据报道，一种经济且可扩展的电化学方案可用于吲哚衍生物的区域选择性3C–H卤化。该策略可在温和条件下使用廉价的（伪）卤化物盐作为唯一试剂，获得大量3-碘，3-溴，3-氯和3-硫氰基吲哚衍生物。无需补充电解质盐。